Navigation Links
A New Treatment Discovered For Acute Lymphoblastic Leukemia

A study undertaken by a group of Spanish scientists, amongst which were members of the University Clinic of the University of Navarra and the Centre for Applied Medical Research// (CIMA) of the same university has recently discovered a new line of treatment for patients with acute lymphoblastic leukemia.

The conclusions of the research have been published in the official journal, Blood, of the American Haematology Association.

It should be noted that acute lymphoblastic leukemia is the most common oncological disease amongst children. This is why the application of this discovery could be highly beneficial for a special group of patients with this disorder – those who show the cellular control pathway known as WNT as altered, - and whose prognosis of this tumour disease is serious.

The WNT pathway is the device that a normal cell needs to activate in order to initiate a process of cell growth and which, once realized, should deactivate itself.

However, it has been shown that, in those groups of acute lymphoblastic leukemia patients with the worst prognoses, this cell control pathway appears to be constantly activated. This phenomenon occurs because the mechanisms controlling this pathway have been silenced due to a process that affects gene transcription and known as metilation. The WNT pathway activated in an ongoing manner gives rise to the expression of specific genes whose function is to activate the growth of tumour cells.

Administration of New Medicinal Drugs
The study has shown, with in vitro trials, that administering a type of medication which impedes this process of metilation or which inactivates the WNT pathway, results in the normalisation of this cell control pathway and, so, impedes the development of tumour cells, inducing the death of the leukemia cells.

In this way, this group of medicines will help to enhance chemotherapy results and raise the rates of survival amongst the se patients.

The discovery provides a rational basis for being able to use a series of drugs for this disease - such as quercetine (which produces a programmed death of acute lymphoblastic leukemia cells) or Decitabine?, medication, already used with other kinds of pathologies.

The next stage in the research will involve the application of trials, based on these studies, in rats, in order to determine which of these drugs are, in fact, efficacious. Once this has been determined, clinical trials with patients will be proposed.

If the results of the application of this research prove to be a success, one consequence may be that the classification of patients with acute lymphoblastic leukemia can be carried out on the basis of the state of activation of the WNT pathway, as this is considered to be a risk factor in the worsening of the disease and in its possible cure.

Source-Bio-Bio Technology
SRI
'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/19/2017)... ... 20, 2017 , ... Today, the Centers for Medicare & Medicaid Services (CMS) ... Payment Models (APMs) in 2017. Clinicians who participate in APMs are paid for the ... of the Administration’s effort to build a system that delivers better care and one ...
(Date:1/19/2017)... ... January 19, 2017 , ... Wells Pharmacy Network announced ... their 503A compounding pharmacy located in Ocala, Florida. , Meeting the Needs ... throughout the United States for high-quality human anti-aging and wellness compounded medications, ...
(Date:1/19/2017)... ... 19, 2017 , ... LabRoots , the leading provider ... world, announces the launch of its newly redesigned website. The sleek new design ... and trending news, vital information on upcoming virtual events and webinars, all while ...
(Date:1/19/2017)... ... 19, 2017 , ... Cosmetic Town, an online plastic surgery community, begins 2017 ... it easier for their readers to get the information they desire. The procedures are ... the techniques used on those particular areas. , “We are excited to streamline our ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... the American Board of Dermatology and fellowship trained Mohs and cosmetic surgeon. After ... of Health, Dr. Li completed his internship in internal medicine at the Emory ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... -- The Global Therapy Partnering Terms and Agreements since ... and agreements entered into by the world,s leading healthcare ... deals by value - Deals listed by company A-Z, ... report provides understanding and access to the partnering deals ... companies. The report provides an analysis of partnering ...
(Date:1/19/2017)... 2017 The drug delivery technology market is ... USD 1,179.20 billion in 2016, at a CAGR of ... chronic diseases, increasing demand for biologics, technological advancements, and ... of this market. Whereas, self-administration & home care and ... growth opportunities for players operating in this market. On ...
(Date:1/18/2017)... , Jan. 18, 2017  EnteroMedics Inc. ... medical devices using neuroblocking technology to treat obesity, ... the pricing of an underwritten public offering of ... to deducting underwriting discounts and commissions and offering ... is comprised of Class A Units, priced at ...
Breaking Medicine Technology: